Mr. Bernanke also reiterated the fact that neither he nor the members of the FOMC team are convinced of the efficacy of another round of full-blown QE asset purchases as regards the mandates of economic growth, reduction in unemployment, and maintenance of benign inflation conditions.

FORBES: In The Lead - QE: Quite Elusive

John Tsai, the worldwide team leader for Lipitor, argues that Lipitor's efficacy may save insurers cost in the long run, and that his drug clearly provides a benefit over standard of care.

FORBES: Magazine Article